Study of a new hepatitis C drug with addiction medications
This study checks how a new hepatitis C medicine (bemnifosbuvir/ruzasvir) interacts with medications used for opioid addiction, such as buprenorphine/naloxone or methadone. It helps doctors understand if the new medicine is safe and effective for people taking these addiction treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are taking a stable dose of either buprenorphine/naloxone or methadone for opioid use disorder.
- You must weigh at least 110 pounds (50 kg) and have a BMI between 18 and 32.
- You cannot have hepatitis B, C, or HIV.
- You must not abuse alcohol or drugs (other than your prescribed treatment).
- You cannot take other prescription or over-the-counter medications (except your assigned buprenorphine/naloxone or methadone).
- You must agree to use effective birth control for 90 days after the last dose if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new implant (BICX104) with or without bupropion to see how safe it is and how it works in the body, compared to an existing treatment (Vivitrol). If you are healthy and not using opioids, you may be eligible to help researchers understand if this implant could be a new option for treatment.
This trial is studying hepatitis C treatment approaches for adults who have a history of injecting drugs, especially those who have injected recently or are on opioid substitution therapy. If you fit the background criteria, the study may offer a treatment pathway and extra support to help you get hepatitis C treated.
This study tests whether adding a new drug called HRS-5635 to your current hepatitis B medicine works better than your current treatment alone. You may qualify if your hepatitis B is already controlled with antiviral pills and your viral levels are very low.
Doctors are testing a new injectable treatment for chronic hepatitis B. This first-in-human study checks the drug's safety and how well it works in people who are already on standard hepatitis B pills.
This is an early-stage safety study testing a new investigational drug (VH4770359) in healthy volunteers. Researchers want to understand how the body processes the drug and ensure it is safe and well-tolerated.
This study looks at women with chronic hepatitis B or C to understand their current health status. It may help researchers find better ways to support patients like you.
Hear when a new Healthy Volunteer Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.